Pemvidutide: Top-line data readout from 48-week MOMENTUM Phase 2 obesity trial expected in Q4 2023; Commenced enrollment in IMPACT Phase 2b NASH trial – Top-line results after 24 weeks of treatment are expected in the first quarter of 2025. HepTcell: Top-line data from Phase 2 clinical trial expected in Q1 2024
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALT:
- Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update
- ALT Upcoming Earnings Report: What to Expect?
- Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
- Altimmune announces initiation of Phase 2b IMPACT trial
- Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)
